Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;45(1):238-247.
doi: 10.1177/0192623316672352. Epub 2016 Oct 23.

Is It Adverse, Nonadverse, Adaptive, or Artifact?

Arun R Pandiri  1 , Roy L Kerlin  2 , Peter C Mann  3 , Nancy E Everds  4 , Alok K Sharma  5 , L Peyton Myers  6 , Thomas J Steinbach  7
Affiliations

Is It Adverse, Nonadverse, Adaptive, or Artifact?

Arun R Pandiri et al. Toxicol Pathol. 2017 Jan.

Abstract

One of the principal challenges facing a toxicologic pathologist is to determine and differentiate a true adverse effect from a nonadverse or an adaptive response. Recent publications from the Society of Toxicologic Pathology (STP) and the European STP provide guidance for determining and communicating adversity in nonclinical toxicology studies. In order to provide a forum to inform and engage in a discussion on this important topic, a continuing education (CE) course was held during the 2016 STP Annual meeting in San Diego, CA. The lectures at this course provided guidance on determining and communicating adversity using case studies involving both clinical pathology and anatomic pathology. In addition, one talk also focused on data quality, study design, and interpretation of artifacts that could hinder the determination of adversity. The CE course ended with a talk on understanding adversity in preclinical studies and engaging the regulatory agencies in the decision-making process. This manuscript is designed to provide brief summaries of all the talks in this well-received CE course.

Keywords: adaptive response; adversity; artifact; nonadverse response.

PubMed Disclaimer

References

    1. Barone S, Jr, Moser VC. The effects of perinatal tebuconazole exposure on adult neurological, immunological, and reproductive function in rats. Toxicol Sci. 2004;77:183. - PubMed
    1. Calabrese EJ, Baldwin LA. Improved method for selection of the NOAEL. Regul Toxicol Pharmacol. 1994;19:48–50. - PubMed
    1. Cavagnaro JA, Beilke LD. What the AEL is the NOAEL?. American College of Toxicology, 35th Annual Meeting; Orlando, FL. 2014.
    1. CDER. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 40CFR Part 261. US Government Printing Office; Washington, DC: 2005.
    1. Clemo FA, Evering WE, Snyder PW, Albassam MA. Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol Pathol. 2003;31 suppl:25–31. - PubMed

MeSH terms

LinkOut - more resources